Insights - The big news this weekend out of the American College of Cardiology's annual scientific session was the comparison of long-term outcomes for two new (and competing) drugs targeting cholesterol,
Read NowRecap - No one has the exact answer, but Mr. King’s post-JP Morgan musings from earlier this year seem relevant yet again. As of Friday’s close, the S&P 500 is actually down year-to-date, while the biotechnology sector is up an impressive 14%, as measured by the IBB. The two have clearly diverged, and it almost seems that investors are fleeing to biotechnology for safety. That’s quite a departure from years past.
Read NowInsights - Zogenix (ZGNX) is divesting of its lead FDA-approved product, the painkiller Zohydro, for $100 million ($30 million in cash up front) and almost $300 million in potential milestone payments. As much as the cash and milestone potential are important to Zogenix, which is re-positioning itself as a pipeline story, more important is that Zogenix is cutting loose the albatross around its neck for the last year and a half.
Read NowInsights - Trevena, Inc. (TRVN) announced on Monday plans to upsize the phase IIb BLAST-AHF trial, testing TRV027 in acute heart failure (AHF), and to focus on the middle dose being tested in the study. The trial will be expanded from 500 to 620 patients and will weight enrolled patients towards what Trevena characterizes as the most promising dose, 5mg/hr, plus standard heart failure therapy versus placebo plus standard of care.
Read NowInsights - Orexigen Therapeutics (OREX) surged early this week with the release of positive interim study results for Contrave, the company’s approved weight loss drug. Public comments from an FDA official on Thursday evening, however, put a damper on the celebration.
Read NowInsights - Intra-Cellular Therapies, Inc. (ITCI) announced a public offering of 4.25 million shares of its common stock on Wednesday morning, prescient in light of the stock’s … Continue Reading
Read Now
